SEQUA Stock Overview
Develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sequana Medical NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.77 |
| 52 Week High | €4.85 |
| 52 Week Low | €0.47 |
| Beta | 0.85 |
| 11 Month Change | -20.62% |
| 3 Month Change | -24.51% |
| 1 Year Change | -68.05% |
| 33 Year Change | -89.51% |
| 5 Year Change | -88.37% |
| Change since IPO | -90.86% |
Recent News & Updates
Shareholder Returns
| SEQUA | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | -14.6% | -2.9% | -2.4% |
| 1Y | -68.0% | 12.8% | 3.5% |
Return vs Industry: SEQUA underperformed the Belgian Medical Equipment industry which returned 13.2% over the past year.
Return vs Market: SEQUA underperformed the Belgian Market which returned 3.7% over the past year.
Price Volatility
| SEQUA volatility | |
|---|---|
| SEQUA Average Weekly Movement | 18.3% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in BE Market | 6.3% |
| 10% least volatile stocks in BE Market | 2.3% |
Stable Share Price: SEQUA's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: SEQUA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 62 | Ian Crosbie | www.sequanamedical.com |
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.
Sequana Medical NV Fundamentals Summary
| SEQUA fundamental statistics | |
|---|---|
| Market cap | €31.19m |
| Earnings (TTM) | -€27.18m |
| Revenue (TTM) | €433.50k |
71.9x
P/S Ratio-1.1x
P/E RatioIs SEQUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEQUA income statement (TTM) | |
|---|---|
| Revenue | €433.50k |
| Cost of Revenue | €101.74k |
| Gross Profit | €331.76k |
| Other Expenses | €27.51m |
| Earnings | -€27.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 76.53% |
| Net Profit Margin | -6,269.81% |
| Debt/Equity Ratio | -111.3% |
How did SEQUA perform over the long term?
See historical performance and comparison